bisphosphonates - malecare.org

Early Use of Zoledronic Acid (Zometa) in Men with Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).

We have long known that Zoledronic Acid (Zometa) decreases a man’s risk of developing skeletal-related events (SREs) in men with castration-resistant advanced prostate cancer (CRPC) and bone metastases. In a phase III study that evaluated efficacy and safety of earlier treatment with Zometa in men with advanced prostate cancer which is still castration-sensitive found that [...]

By Malecare|2017-10-19T10:50:06-04:00March 12th, 2013|Advanced Prostate Cancer, bisphosphonates, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Zometa|0 Comments

Some Side Effects of Androgen Deprivation Therapy (ADT) Induced by Estrogen Deficiency

Androgen deprivation therapy (ADT) is an old standby for the treatment of men with metastatic or advanced prostate cancer. We have long known that testosterone plays an integral role in the progression of prostate cancer, thus we often use it as an initial treatment for men who become metastatic. ADT is used both for men [...]

By Malecare|2017-10-19T10:51:01-04:00July 3rd, 2012|Advanced Prostate Cancer, bisphosphonates, Bone Mineral Density, Drugs & Treatments, General Information, Hormone Therapy, How We Live, Prostate Ponderings, Uncategorized, Understanding APC|0 Comments

Xgeva (Denosumab) Rejected By the FDA for Use in Men with Advanced Prostate Cancer Who Do Not have Bone Mets

Xgeva (denosumab), which has already been approved by the Food and Drug Administration (FDA) for the prevention fractures in men with advanced prostate cancer that has already migrated to the bone, has been rejected by the FDA to expand the use of the drug to delay the spread of tumors in men without metastases to [...]

By Malecare|2012-04-27T11:01:50-04:00April 27th, 2012|Advanced Prostate Cancer, bisphosphonates, Bone Metastases, denosumab - Xgeva, Drugs & Treatments, FDA, Uncategorized, Understanding APC|4 Comments

Osteonecrosis Of The Jaw While Taking Zometa & Xgeva

The use of denosumab (Xgeva) as an alternative to the more commonly prescribed zoledronic acid (Zometa) to slow down the development of bone metastases in men with advanced prostate cancer is becoming more common. The most common concern for men taking Zometa and now Xgeva has been osteonecrosis of the jaw. Osteonecrosis of the jaw [...]

By Malecare|2017-10-19T10:51:53-04:00December 12th, 2011|Advanced Prostate Cancer, bisphosphonates, denosumab - Prolia, denosumab - Xgeva, Drugs & Treatments, Uncategorized, Understanding APC, Zometa|9 Comments

XGEVA Delays The Onset Of Bone Metastases In Men With Non-Metastastic Castrate Resistant Prostate Cancer

Amgen announced that they have published the results from their Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with non-metastatic castration-resistant prostate cancer (CRPC). The results were published in The Lancet. The study found XGEVA significantly prolonged bone metastasis-free survival, [...]

By Malecare|2020-02-04T10:43:48-05:00November 23rd, 2011|Advanced Prostate Cancer, bisphosphonates, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, Metastases, Uncategorized, Understanding APC|2 Comments